Perspectives and achievements with Rational Pharmacotherapy Meeting under Danish EU presidency...
33
Perspectives and achievements with Rational Pharmacotherapy Meeting under Danish EU presidency Implementation of Rational Pharmacotherapy Copenhagen , November 6, 2002 WHO/EURO Kees de Joncheere, Regional Adviser Pharmaceuticals
Perspectives and achievements with Rational Pharmacotherapy Meeting under Danish EU presidency Implementation of Rational Pharmacotherapy Copenhagen, November
Perspectives and achievements with Rational Pharmacotherapy
Meeting under Danish EU presidency Implementation of Rational
Pharmacotherapy Copenhagen, November 6, 2002 WHO/EURO Kees de
Joncheere, Regional Adviser Pharmaceuticals
Slide 2
Overview of the presentation Pharmaceutical policies in Europe
Rational use of medicines Comparing European countries Improving
the prescribing and use of medicines Concluding remarks
Slide 3
Challenges for pharmaceutical policies in Europe Equitable
access for patients to effective, safe and good quality medicines
Enhancing appropriate use of medicines for better health outcomes
Ensuring value for money Balance with industrial policy objectives
Values underpinning health systems : equity, quality, solidarity,
participation and accountability
Slide 4
Pharmaceutical policies and the EU EU regulatory framework and
legislation National responsibilities on pricing and reimbursement
(subsidiarity) Transparency directive Industrial policy
communication 1995 Single market communication 1998 Public health
communication 2000 Portugal 2000, EU MINE, DG5/health High Level
committee, G 10, Review 2000-1
Slide 5
Medicines and Public health in EU Future of the European system
for evaluations and supervision of medicinal products Relevance of
the added therapeutic value of medicinal products ( registration
criteria ? Placebo or comparator?) Aspects determining innovation
and research Rational use of medicinal products Importance and
evolution trends for the information systems Increasing use of
generic medicines Adoption of EU public health action plan,
2002
Slide 6
Slide 7
Slide 8
Slide 9
Slide 10
Rational use of medicines Right patient with right indication
Right medicine Right dose/administration Right information Right
moment to stop or change
Slide 11
Inappropriate use leads to Adverse effects Sub-optimal outcomes
Waste of resources ( money, health professionals and patients
time)
Slide 12
Why are drugs not used rationally ? Lack of training and
knowledge Marketing practices Financial incentives for irrational
use Availability problems Patient expectations Prescribing as a
means to finish the consultation Health systems and services
effects
Slide 13
Slide 14
Slide 15
Slide 16
Slide 17
Slide 18
Measuring and monitoring the use of medicines Describe and
compare existing situations and patterns Identify differences and
potential problems Monitor results of interventions Lessons drawn
from other countries` experiences
Slide 19
From drug utilisation to cost- effective intervention (1) Drug
utilisation studies tend to be descriptive, aggregated data : WHAT?
Indicator studies more focused on rational drug use: WHAT? HOW
MUCH? Qualitative studies WHY?
Slide 20
From drug utilisation to cost- effective intervention (2)
Intervention studies HOW MUCH? WHY? (intervention) HOW MUCH NOW?
Conclusion DOES IT WORK? IS THE INTERVENTION EFFECTIVE? Management
studies IS THE INTERVENTION REPRODUCABLE? IS IT
COST-EFFECTIVE?
Slide 21
Examples of indicators (WHO/INRUD) Prescribing indicators
Average number of drugs per encounter (